Romidepsin – March 2026

Injection set including 1 vial powder for injection 10 mg and 2 mL solvent

  • Brand names:
    • ROMIDEPSIN-REACH
  • Pharmaceutical Company:
    • REACH PHARMACEUTICALS PTY LTD
  • Condition/Indication: Relapsed or refractory peripheral T-cell lymphoma
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026